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a b s t r a c t 
The Wilms tumor protein 1 (WT1) transcription factor has been associated in malignant melanoma
with cell survival and metastasis, thus emerging as a candidate for targeted therapy. A lysine–arginine
rich peptide, WT1-pTj, derived from the ZF domain of WT1 was evaluated as an antitumor agent against
A2058 human melanoma cells and B16F10-Nex2 syngeneic murine melanoma. Peptide WT1-pTj quickly
penetrated human melanoma cells and induced senescence, recognized by increased SA- β-galactosidase
activity, enhanced transcriptional activity of p53, and induction of the cell cycle inhibitors p21 and p27.
Moreover, the peptide bound to p53 and competed with WT1 protein for binding to p53. WT1-pTj
treatment led to sustained cell growth suppression, abrogation of clonogenicity and G2 / M cell cycle
arrest. Notably, in vivo studies showed that WT1-pTj inhibited both the metastases and subcutaneous
growth of murine melanoma in syngeneic mice, and prolonged the survival of nude mice challenged
with human melanoma cells. The 27-amino acid cell-penetrating WT1-derived peptide, depends on C 3
and H 16 for effective antimelanoma activity, inhibits proliferation of WT1-expressing human tumor cell
lines, and may have an effective role in the treatment of WT1-expressing malignancies. 
C © 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. All rights reserved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
The Wilms tumor protein 1 (WT1) is a transcription factor that
plays an important role in cellular development and cell survival. It
is abnormally expressed in several human cancers and could be a
target of therapeutic agents. Structurally, the WT1 protein contains
four C 2 H 2 Kr ¨upple-like zinc-ﬁngers (ZF) in the C-terminal domain,
which are important for DNA binding, RNA binding and interaction
with other proteins [ 1 ]. Originally described as a tumor suppressor
gene in pediatric nephroblastoma [ 2 , 3 ], the overexpression, confor-
mational changes and cytoplasmic localization of WT1 in different
malignancies such as mesothelioma, ovarian cancer, leukemia, os-
teosarcomas, glioblastomas and malignant melanomas [ 4 , 5 ] demon-
strated oncogenic properties of this protein. In malignant melanoma, This is an open-access article distributed under the terms of the Creative Com- 
mons Attribution-NonCommercial-No Derivative Works License, which permits non- 
commercial use, distribution, and reproduction in any medium, provided the original 
author and source are credited. 
Abbreviations: C PEP, control peptide; CL-ELISA, chemiluminescence ELISA; CPP, 
cell-penetrating peptide; pTj, Trojan peptide; SA- βGal, senescence-associated β- 
galactosidase; TMZ, Temozolomide; WT1, Wilms tumor protein 1; ZF, zinc-ﬁnger. 
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2211-5463/ $ 36.00 c © 2014 The Authors. Published by Elsevier B.V. on behalf of Federation o
http://dx.doi.org/10.1016/j.fob.2014.01.007 the most aggressive and lethal form of skin cancer, WT1 expression
has been reported in more than 80% tumor cells but not in epidermal
keratinocytes, melanocytes and benign melanocytic nevi in vivo [ 6 ].
Notably, RNAi silencing of WT1 induces apoptosis in B16F10 murine
melanoma cells [ 7 ] and displays antimetastatic activity [ 8 ]. 
The oncogenic role of WT1 in cancer stimulates attempts at neu-
tralizing this tumor-associated antigen. Recently, the anticancer ther-
apy that employs peptides, which can directly target cancer cells, has
emerged as an alternate strategy to restrain the progression of tumor
growth and metastases [ 9 ]. Antitumor peptides may act binding to
and inhibiting oncogenes or proteins with aberrant expression in tu-
mor cells. They cause cell cycle arrest and / or induce apoptosis, block
signaling mediators and receptors, inhibit angiogenesis, and mediate
tumor environment homing of cytotoxic peptide sequences [ 10 –15 ].
Certain peptides are cell-penetrating (CPPs) or Trojan peptides, with
short amphipathic and cationic sequences that permit their pene-
tration across the cell membrane, and thus exert direct anticancer
activity [ 16 ]. These peptides may be carriers of a variety of antitumor
molecules [ 17 , 18 ]. 
In the present work, we show that a novel WT1-derived pep-
tide (WT1-pTj) is a cell-penetrating antitumor agent that suppresses
both proliferation and clonogenicity of B16F10-Nex2 melanoma cellsf European Biochemical Societies. All rights reserved. 
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lhrough an irreversible G2 / M cell cycle arrest and induction of cel- 
ular senescence. In addition to morphological changes and irre- 
ersible growth inhibition, senescent cells expressed the senescence- 
ssociated β-galactosidase and formed hetero-chromatin foci [ 19 ], 
ssociated with enhanced transcriptional activation of p53, and accu- 
ulation of cyclin-dependent kinase inhibitors p21 Cip1 and p27 Kip1 , 
hich have been used as markers of senescence [ 20 ]. 
Most importantly, WT1-pTj displayed a remarkable antimetastatic 
ctivity in the syngeneic B16F10-Nex2 melanoma model and pro- 
onged survival of nude mice subcutaneously challenged with human 
2058 melanoma cells. Both results emphasize the potential of this 
ovel antitumor peptide to be developed as a therapeutic drug. 
The potential use of bioactive peptides as anti-cancer drugs has 
een investigated in our laboratory and considerable progress has 
een made using peptides derived from immunoglobulins and from 
ranscription factors [ 21 , 22 ]. 
. Materials and methods 
.1. Peptides 
A 27-residue synthetic peptide (WT1-pTj) corresponding to amino 
cids 349–375 of the human WT1 protein (GenBank: CAI95758 ) and 
he control peptide (C PEP, with C3A and H16A) were synthesized 
y Peptide 2.0 Inc. (Chantilly, VA) at 90–99% purity, with amidated 
-terminal amino acid, and were completely solubilized in PBS or 
ulture medium. The WT1-pTj peptide is 100% identical to the related 
equence of mouse WT1 protein, corresponding to amino acids 426–
52 (GenBank: NP659032 ). Structures and molecular masses of the 
eptides are depicted on Table 1 . 
.2. Cell lines and culture conditions 
Cell lines were originally obtained from Ludwig Institute for Can- 
er Research, S ˜ ao Paulo, Brazil, or donated by Prof. Luis F. Lima Reis, 
ospital Sirio-Libanez, S ˜ ao Paulo, Brazil. These are long established 
ell lines, acquired from public culture collections or transferred from 
udwig Institute in New York, and maintained in appropriate condi- 
ions to serve as standard tumor cell lines for local studies and collabo- 
ative research. Animal experiments were carried out using protocols 
pproved by the Ethics Committee for Animal Experimentation of 
ederal University of Sao Paulo, Brazil (CEP No. 1280 / 10). 
The murine melanoma B16F10-Nex2 subline was established at 
he Experimental Oncology Unit (UNONEX), Federal University of 
 ˜
 ao Paulo, UNIFESP, as described [ 23 ] and used ever since in sub- 
utaneous and metastatic syngeneic models in mice. The human tu- 
or cell lines A2058 and SK-MEL-28 (melanoma), MCF-7 and MDA- 
B231 (breast carcinoma), OVCAR-3 (ovarian carcinoma) and HL-60 
acute leukemia) were maintained in complete medium consisting of 
PMI-1640 (Gibco, Grand Island, NY) supplemented with 10 mM N- 
-hydroxyethylpiperazine-N 2 ethanesulphonic acid (HEPES; Sigma–
ldrich, St. Louis, MO), 24 mM sodium bicarbonate, 40 mg / l gentam- 
cin (Hipolabor, Minas Gerais, Brazil), pH 7.2, and 10% fetal bovine 
erum (FBS; Gibco, Grand Island, NY). 
The human ﬁbroblast cell line HFF and mouse embryonic ﬁbrob- 
asts (MEFs) were a gift from Luis F. Lima Reis, Hospital Sirio-Libanez, 
 ˜
 ao Paulo. The HFF cell line was maintained in minimum essential 
edium Eagle (Gibco, Grand Island, NY) with 2 mM l -glutamine and 
arle’s balanced saline solution adjusted to contain 1.5 g / l sodium 
icarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium 
yruvate, and 10% FBS. MEF cell line was maintained in DMEM (Gibco, 
rand Island, NY) medium supplemented as described above. All cell 
ines were cultured at 37 ◦C, in humid atmosphere and 5% CO 2 . 2.3. Confocal microscopy 
A2058 human melanoma cells (4 × 10 4 ) were plated in round 
coverslips and incubated at 37 ◦C for 24 h. Cells were treated with 
0.5 mM ﬂuorescein isothiocyanate (FITC)-labeled-WT1-pTj for 1 h at 
37 ◦C. After incubation, tumor cells were ﬁxed and permeabilized with 
methanol for 15 min at room temperature, followed by blocking with 
0.2% gelatin for 10 min at 37 ◦C. Nuclear staining was carried out with 
10 μg / ml of DAPI (Invitrogen, Eugene, OR). Cells were then washed 
in PBS and coverslips mounted onto slides with 4 μl Vectashield 
(Sigma, St. Louis, MO) and imaged using a Carl Zeiss LSM780 confocal 
microscope (Jena, Germany). 
For time dependent WT1-pTj localization, A2058 cells were incu- 
bated for 15 min, 1 and 24 h with 0.5 mM biotinylated-WT1-pTj (b- 
WT1-pTj), washed 3 times in PBS, and ﬁxed with 3.7% paraformalde- 
hyde for 30 min. Cells were then permeabilized in 0.1% Triton X-100 
for 30 min followed by blocking for 1 h with 150 mM NaCl, 50 mM Tris 
and 0.25% BSA, all from Sigma–Aldrich, MO. After washing in PBS, cells 
were incubated with 10 μg / ml DAPI and streptavidin-FITC (1:200 
from stock solution) used as secondary ﬂuorophore for biotinylated 
peptide, and were both incubated for 15 min at 37 ◦C. Stained cells on 
coverslips were examined for peptide intracellular localization using 
a Confocal Leica SP5 microscope with a 100 × oil immersion objec- 
tive (Leica, Wetzlar, Germany). The Z series was acquired according 
to sampling criteria built into the software for sequential imaging 
of DAPI, which stains the nucleus (blue, excitation / emission = 350 / 
470 nm) and FITC, which monitors peptide localization (green, at 
excitation / emission = 488 / 525 nm). Images were processed with 
the ImageJ software ( http: // rsb.info.nih.gov / ij / ). 
2.4. Cell viability 
The effects of WT1-pTj and C PEP on cell viability were deter- 
mined by Trypan blue exclusion assay. For EC 50 determination, cells 
(5 × 10 3 / well) were seeded and cultivated in 96-well plates for 12 h 
at 37 ◦C. Cells were incubated with increasing concentrations of the 
peptides (0–1 mM) for 24 h, were detached with Trypsin–EDTA 0.25% 
solution (Sigma–Aldrich, St. Louis, MO) and the number of viable cells 
counted using a Neubauer chamber (Electron Microscopy Sciences, 
Hatﬁeld, PA). The growth kinetics of A2058 cells (10 3 / well) during 
96 h in presence of WT1-pTj or C PEP at different concentrations was 
determined by cell counting every 24 h. 
2.5. Colony formation 
Anchorage-independent growth of peptide-treated melanoma 
cells was determined in soft agar. A2058 cells (10 3 ) in culture medium 
with 10% FBS, 0.35% agar and 0.5 mM WT1-pTj or C PEP, were plated 
on a bottom agar layer containing medium, 10% FBS and 1% agar in a 
6-well culture plate. After 6 days of cell plating, more peptide (0.5 mM 
WT1-pTj or C PEP) and culture medium (300 μl) were added to the 
corresponding wells. Colonies were stained with 0.5% crystal violet 
in 70% ethanol and counted 11 days after initial treatment using a 
vertical microscope. 
Alternatively, clonogenicity was tested in peptide-treated A2058 
cells (10 3 ) seeded in 6-well plates. After 5 days, 500 μl of 0.5 mM 
WT1-pTj or C PEP or culture medium were added in the corresponding 
wells. 10 days after plating, colonies were stained with 0.5% crystal 
violet in 70% ethanol for 10 min and counted in a stereomicroscope. 
To assess the colony formation ability after drug removal, A2058 
cells (10 3 ) were left untreated or treated with 0.5 mM WT1-pTj, 
0.5 mM C PEP or 0.5 mM Temozolomide (TMZ; Sigma–Aldrich, St. 
Louis, MO). After 4 days, cells were harvested and equal numbers of 
untreated and treated cells were seeded (10 3 ) in 6-well plates and 
cultivated for additional 4 days in fresh media. Colonies were stained 
and quantiﬁed as mentioned above. 
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Table 1. 
Peptide sequences and molecular mass. 
Name Sequence Mass (Da) 
WT1-pTj KDCERRFSRSDQLKRHQRRHTGVKPFQ-NH 2 3395.84 
b-WT1-pTj biotin-CGGKDCERRFSRSDQLKRHQRRHTGVKPFQ-NH 2 3839.38 
FITC-WT1-pTj KDCERRFSRSDQLKRHQRRHTGVKPFQK-FITC 3914.53 
C PEP KDAERRFSRSDQLKRAQRRHTGVKPFQ-NH 2 3297.71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2.6. Chemiluminescence ELISA (CL-ELISA) 
Binding of p53 to WT1-pTj was examined by CL-ELISA. Recom-
binant p53 (Novus Biotechnology, Littleton, CO), 100 ng in 50 μl of
carbonate buffer (15 mM Na 2 CO 3 , 35 mM NaHCO 3 , 0.2 g / l NaN 3 ,
pH 9.6) was left to adhere overnight at 4 ◦C onto wells of maxisorp
opaque ELISA plates (Nunc TM , Nalge Nunc International, Dusseldorf,
Germany). Plates were blocked for 1 h at 37 ◦C with 1% BSA in PBS-
Tween 0.05%. After 3 washes in PBS-Tween 0.05%, 1 μM biotinylated-
WT1-pTj was incubated for 1 h at 37 ◦C. Streptavidin-peroxidase
(1:2000; Sigma–Aldrich, St. Louis, MO) was added and the reaction
was evaluated by chemiluminescence using ECL solution (Millipore,
Billerica, MA) in a luminometer (SpectraMax, Molecular Devices Soft-
ware Pro 5.2, Sunnyvale, CA) at 470 nm. Chemiluminescence readings
are expressed as Relative Luminescence Units (RLU). 
Competitive ELISA was performed to investigate whether WT1-pTj
competes with WT1 protein for binding to p53. To that end, 100 ng of
recombinant p53 protein in carbonate buffer was dispensed in wells
of ELISA microplate (96-well) and left overnight at 4 ◦C. Blocking
and washing preceded the addition of 100 ng of recombinant WT1
(Jena Bioscience, Jena, Germany), followed by 1-h incubation at 37 ◦C.
After washing 3 times in PBS-Tween 0.05%, WT1-pTj or C PEP were
incubated at different concentrations for 1 h at 37 ◦C. Binding of WT1
to p53 was detected using anti-WT1 monoclonal antibody (1:1000,
Millipore, Billerica, MA). After incubation for 1 h at 37 ◦C, the plate
was extensively washed in PBS-Tween 0.05% and the secondary anti-
mouse IgG coupled to peroxidase (1:2000; Sigma–Aldrich, St. Louis,
MO) was added. The plate was washed 3 times in PBS and the reaction
was evaluated by chemiluminescence as described above. 
2.7. Luciferase reporter assay 
Detection of p53 activity was performed using the Cancer 10-
pathway Reporter Array (SA Biosciences, Fredrick, MD) following the
manufacturer’s instructions. After A2058 melanoma cells transfec-
tion, they were left untreated or treated with 0.5 mM WT1-pTj or
0.5 mM C PEP, and further incubated for 24 h. Luciferase activity was
measured using the Dual Luciferase Assay system (Promega, Madi-
son, WI) on a luminometer (SpectraMax, Molecular Devices Software
Pro 5.2, Sunnyvale, CA). Fireﬂy luciferase was the experimental re-
porter and Renilla luciferase was the internal control for normalizing
transfection efﬁciencies. 
2.8. SA- β-galactosidase activity 
A2058 cells (10 3 ) were cultivated in 6-well plates and then left
untreated or treated with 0.5 mM WT1-pTj, 0.5 mM C PEP or 0.5 mM
TMZ (Positive control) [ 24 ] for 4 days. Cells were washed to remove
the peptides and TMZ, following incubation with complete fresh
medium for additional 3 days. SA- β-galactosidase activity was de-
tected with the Senescence β-galactosidase Kit (Cell Signaling, Bev-
erly, MA), following the manufacturer’s instructions. To quantify SA-
β-galactosidase activity, at least 100 cells were counted in three ran-
dom ﬁelds using an inverted light microscope. 2.9. Lysosomal vacuolation observed with acridine orange 
Lysosomes from A2058 cells (10 3 / well) plated in 4-well chambers
and treated or not with 0.5 mM WT1-pTj or 0.5 mM C PEP for 4 days
at 37 ◦C, were observed following incubation with 1 μg / ml acridine
orange (Sigma–Aldrich, St. Louis, MO) for 15 min. A Nikon BioStation
IM-Q inverted microscope (red, excitation / emission = 490 / 650 nm)
was used. 
2.10. Cell cycle analysis 
A2058 cells were seeded in 12-well plates at 2 × 10 5 cells per
well and incubated overnight without serum for cell cycle synchro-
nization. Cells were treated or not with 0.5 mM WT1-pTj or 0.5 mM
C PEP for 24 h. After incubation, cells were harvested with trypsin–
EDTA 0.25%, washed with PBS and centrifuged. Pellets were stained
with propidium iodide (PI) in 0.1% Triton X-100, 0.1% sodium citrate,
50 μg / ml PI (Sigma–Aldrich, St. Louis, MO) and 300 μg / ml RNAse A
(Invitrogen, Eugene, OR) for 30 min at 4 ◦C in the dark. Flow cytometric
analysis used a FACSCanto II ﬂow cytometer (Becton Dickinson, San
Jose, CA). Post-acquisition analysis used the FlowJo software (Tree
Star Inc., Ashland, OR). For evaluation of DNA content, 20,000 events
were acquired from at least three independent experiments. 
2.11. Western blotting 
A2058 cells (10 6 ) treated with 0.5 mM WT1-pTj or 0.5 mM C PEP
for 24 h after cell cycle synchronization or untreated cells (Control)
were lysed for protein extraction with RIPA buffer (50 mM Tris–Cl, pH
7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and
0.1% SDS) supplemented with protease and phosphatase inhibitors
(Sigma–Aldrich, St. Louis, MO). After 20 min incubation on ice, the cell
lysates were collected after centrifugation at 1500 rpm. The protein
concentration of lysates was determined by Bradford method (Bio-
Rad, Hercules, CA). Proteins (15 μg) were separated by SDS–PAGE
and transferred to a nitrocellulose membrane (Millipore, Billerica,
MA). Immunoblotting was run with antibodies against p53, phospho-
p53 (Ser15, Ser392), p27, p21, cyclin B1, phospho-cdc2 (Tyr15), and
β-actin, all purchased from Cell Signaling Technology (Beverly, MA).
β-actin was used as the protein loading control. Secondary antibodies
conjugated with IgG horseradish peroxidase were purchased from
Sigma–Aldrich (St. Louis, MO) and immunoreactivity was detected
using the Immobilon solution (Millipore, Billerica, MA). Protein bands
were detected using the UVItec Alliance gel documentation system
(UVItec, Cambridge, UK). 
2.12. Experimental melanoma models in vivo 
The Ethics Committee for animal experimentation of Federal Uni-
versity of S ˜ ao Paulo approved all experiments using mice, CEP No.
1280, 2010. All in vivo experiments were performed at least twice. 
In the lung metastasis model, male, six-to-eight week-old, C57BL /
6 mice were challenged e.v. with 5 × 10 5 syngeneic B16F10-Nex2
melanoma cells in 100 μl of PBS. Animals ( n = 5 per group) were
treated the day after tumor challenge, with 5 daily i.p. doses of 300 μg
of C PEP, 300 μg of WT1-pTj or vehicle (PBS). After 14 days, lungs
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Fig. 1. Protective effect of WT1-pTj in vivo . (A) Lung colonization of B16F10-Nex2 
endovenously inoculated in C57BL / 6 mice. Animals received 5 i.p. doses of 300 μg of 
C PEP, 300 μg of WT1-pTj or vehicle (PBS) on consecutive days; * p = 0.02 versus C 
PEP. (B) Effect of WT1-pTj on subcutaneous growth of B16F10-nex2 melanoma tumor. 
Once nodules reached 200 mm 3 , mice were randomized and received 5 alternate i.p. 
injections of 300 μg of WT1-pTj or C PEP; * p < 0.05 versus C PEP. (C) Effect of WT1-pTj 
on A2058 tumor growth in nude mice. Animals were treated with peritumor injections 
of 300 μg of WT1-pTj, 300 μg of C PEP or vehicle (PBS) for 5 consecutive days, starting 
on day 1 post-tumor cell challenge; * p < 0.05 in comparison with C PEP. (D) Survival 
of nude mice grafted with human melanoma after treatment with WT1-pTj, C PEP or 
PBS; n = 5 mice per group; * p = 0.0185 in comparison with C PEP. ere collected from animals of each group, and inspected for lung 
olonization. 
In the syngeneic subcutaneous (s.c.) tumor model, B16F10-Nex2 
ells (10 5 / animal) were inoculated into the right ﬂank of C57BL / 
 mice. Once nodules reached 200 mm 3 , mice ( n = 5 per group) 
eceived 5 i.p. doses of 300 μg of WT1-pTj, 300 μg of C PEP or PBS on 
lternate days. The human A2058 melanoma cells (4 × 10 6 / animal) 
ere injected subcutaneously in athymic nude mice ( n = 5 per group), 
reated with 300 μg of C PEP, 300 μg of WT1-pTj or vehicle (PBS) for 5 
onsecutive days. Peritumor therapy started the day after inoculation 
f melanoma cells. The tumor volume ( V ), measured daily with a 
aliper, was calculated by the formula V = 0.52 × d 2 × D , where 
 and D are the short and long diameters of the tumor, respectively. 
ice were sacriﬁced when the tumor size reached 3000 mm 3 . 
.13. Statistical analysis 
Data are expressed as mean values ± standard deviations (SD) of 
ultiple replicates. All data are representative of at least two indepen- 
ent experiments. p -Values were calculated by Student’s t -test and 
onsidered signiﬁcant if less than 0.05. Statistical differences among 
reated groups in the s.c. tumor model were assessed by the Gehan–
reslow–Wilcoxon test. The Kaplan–Meier method was used to cal- 
ulate survival curves, and log-rank test was used to compare the 
urvival rates of different groups. All statistical analyses were done 
sing Prism Graphpad Software (San Diego, CA). 
. Results 
.1. WT1-pTj displays effective antimelanoma activity in vivo 
The WT1-pTj peptide but not the C PEP control peptide, with two 
mino acids replaced by alanine, signiﬁcantly reduced the number of 
ung metastatic nodules in the syngeneic B16F10-Nex2 melanoma 
odel ( Fig. 1 A). Melanoma cells were injected endovenously in 
57Bl / 6 mice and treatment consisted in 5 daily i.p. injections of 
00 μg of either peptide or vehicle (PBS), starting the day after tumor 
ell challenge. 
By using subcutaneous B16F10-Nex2 melanoma graft in syngeneic 
ice, the tumor was left to grow until it reached 200 mm 3 . Pep- 
ides were then injected i.p., with 5 doses of 300 μg / animal in al- 
ernate days. WT1-pTj rather than the C PEP control clearly delayed 
elanoma growth, even after tumor establishment ( Fig. 1 B). 
The WT1-pTj protective activity was also evaluated using a human 
elanoma xenograft in nude mice. Animals were challenged with 
uman melanoma cells s.c., and treated daily, for 5 days, with 300 μg 
T1-pTj or C PEP. Peritumor therapy started one day after inoculation 
f melanoma cells. As observed in Fig. 1 C, WT1-pTj was effective in 
elaying the growth of human melanoma-bearing nude mice using in 
itu injections. Moreover, the survival of mice treated with WT1-pTj 
as signiﬁcantly prolonged in comparison to that of the PBS and C 
EP control groups ( Fig. 1 D). 
It should be noted that in all in vivo experiments mice main- 
ained healthy physical appearance, normal activity levels and normal 
eight throughout the study period, showing no toxic effects of pep- 
ides. Notwithstanding, an effective antimetastatic activity and a re- 
arkable therapeutic efﬁcacy of WT1-pTj peptide against melanoma 
ere shown. 
.2. WT1-pTj peptide rapidly translocates into human melanoma cells 
The direct effects of WT1-pTj on human melanoma cells were 
nvestigated. Considering the characteristics of the peptide, Trojan- 
ike properties, and effects related to zinc-ﬁnger interactions could be 
redicted. In fact, WT1-pTj is a 27-mer lysine–arginine rich peptide, 
rom the C-terminal region of WT1, which contains part of the second zinc-ﬁnger (ZF) domain of WT1. The analogous peptide, with alanine 
substitutions at cysteine-3 and histidine-16, both involved in the ZF 
motif, was used as a suitable control peptide (C PEP). Viable non- 
permeabilized A2058 human melanoma cells were exposed to 0.5 mM 
FITC-labeled WT1-pTj for 1 h. Using confocal microscopy, we observed 
that the peptide entered the cells showing a diffuse distribution in the 
cytoplasm and was also seen in the nucleus within 1 h, conﬁrming 
the Trojan nature of the peptide ( Fig. 2 A). 
A2058 cells were also incubated with biotinylated-WT1-pTj (b- 
WT1-pTj) for 15 min, 1 and 24 h, then were ﬁxed and permeabilized, 
followed by incubation with streptavidin-FITC and DAPI. Images taken 
15 min after exposure to 0.5 mM of b-WT1-pTj showed predominantly 
membrane and cytoplasmic staining. After 1 and 24 h the peptide was 
completely distributed in the cells, particularly in the nucleus where 
it colocalized with nuclear DNA ( Fig. 2 B). 
3.3. WT1-pTj inhibits the proliferation of WT1-expressing tumor cells 
The effect of WT1-derived peptide on cell viability was determined 
by Trypan blue exclusion staining. Assuming the potential oncogenic 
role of WT1 in tumor cells [ 25 ], the peptide could modify this phe- 
notype by structural interference. WT1-pTj did not induce cell death, 
but inhibited the proliferation of different WT1-expressing cancer 
cell lines ( Table 2 ). As indicated by EC 50 values, WT1-pTj induced 
growth inhibition of B16F10-Nex2 murine melanoma cells, A2058 
and SK-MEL-28 human melanoma cells, MCF-7 and MDA-MB231 hu- 
man breast cancer cells and OVCAR-3 human ovarian cancer cells, 
and was less effective against HL-60 human leukemia cells. Treat- 
ment with the peptide blocked cell proliferation but did not induce 
a death mechanism in vitro . No effect on the proliferation of nor- 
mal murine or human ﬁbroblasts was detected, showing a selective 
activity of WT1-pTj on tumor cells. 
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Fig. 2. Intracellular distribution of WT1-pTj in A2058 human melanoma cells. (A) Cells 
were treated with FITC-labeled WT1-pTj for 1 h at 37 ◦C and visualized by confocal mi- 
croscopy. Sequence (Z-stacks) showing the distribution of FITC-labeled peptide (green) 
and the nuclei stained with DAPI (blue). Bar = 10 μm. (B) Co-localization of WT1-pTj 
and nuclear DNA in human melanoma cells. A2058 cells were treated with biotinylated 
WT1-pTj for 24 h, ﬁxed with paraformaldehyde, and permeabilized with Triton X-100. 
(a) Differential interference contrast (DIC) image; (b) Cells stained with DAPI; (c) Cells 
treated with streptavidin-FITC; (d) Merge, showing nuclear colocalization of WT1-pTj. 
Inserts: high magniﬁcation of cells indicated by arrows. Scale bar = 10 μm. (For inter- 
pretation of the references to colour in this ﬁgure legend, the reader is referred to the 
web version of this article.) 
Table 2. 
Antiproliferative activity of WT1-pTj on WT1-expressing tumor cell lines and nontumor 
forming cell lines. 
Cell lines EC 50 
a (mol / l x 10 −3 ) 
A2058 human melanoma 0.455 ± 0.032 
SK-MEL-28 human melanoma 0.680 ± 0.020 
B16F10-Nex2 murine melanoma 0.466 ± 0.067 
MCF-7 human breast cancer 0.247 ± 0.058 
MDA-MB231 human breast cancer 0.759 ± 1.40 
OVCAR-3 human ovarian cancer 0.208 ± 0.02 
HL-60 human acute leukemia > 1 
HFF human foreskin ﬁbroblast > 1 
MEF murine embryonic ﬁbroblast > 1 
a EC50 is the concentration that decreases viability by 50% in a dose-dependent survival 
curve. 
 
 
 
 
 
 
 
 
Fig. 3. Effects of WT1-pTj on proliferation and clonogenic ability of human melanoma 
cells. (A) A2058 cells (10 3 / well) were treated with WT1-pTj (left) or C PEP (right) at 
the indicated concentrations for 96 h, and cell proliferation was daily monitored by 
Trypan blue exclusion assay; (B) A2058 cells were suspended in 300 μl of 0.5 mM 
WT1-pTj, 0.5 mM C PEP, or unsupplemented culture medium (Control) and cultivated 
on soft-agar medium. The number of colonies was determined 11 days after the ﬁrst 
treatment; * p < 0.02. (C) Representative photomicrographs of colony formation assay. 
A2058 cells were plated on (a) untreated culture medium (Control), (b) medium treated 
with 0.5 mM C PEP, or (c) treated with 0.5 mM WT1-pTj. After 5 days, culture media 
were aspirated and fresh medium with the respective peptides at 0.5 mM was added. 
After 10 days incubation, colonies were stained with crystal violet and counted on a 
stereomicroscope. Data represent means ± SD of three independent experiments. (For 
interpretation of the references to colour in this ﬁgure legend, the reader is referred to 
the web version of this article.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.4. WT1-pTj but not C PEP displays strong antiproliferative effects on 
human melanoma cells 
Since WT1 gene is essential for melanoma cells proliferation and
metastasis [ 26 , 27 , 8 ] we examined whether WT1-pTj and more specif-
ically, the truncated ZF-motif of WT1-pTj, displayed anti-melanoma
proliferative effects. Human A2058 melanoma cells were incubated
with WT1-pTj or C PEP (A 3 C, A 16 H) at 0.125 to 0.5 mM and the cell
number of viable cells determined every 24 h for 4 days. We found
that treatment with WT1-pTj resulted in a dose-dependent inhibition
of proliferation of melanoma cells when compared to untreated cells.The number of cells remained stable from 24 to 96 h when treated
with WT1-pTj at 0.5 mM, suggesting that the peptide had a sustained
cytostatic effect on these cells. No signiﬁcant changes on proliferation
were observed in C PEP-treated cells, except at the highest dose after
96 h of incubation ( Fig. 3 A). 
Han et al. [ 28 ] reported on the transfection of MCF-7 human breast
cancer cells with constructs containing only the ZF domains of WT1
and consequent reduction in the expression of proteins important for
the survival and tumor cell proliferation, such as c-myc, Bcl-2 and
amphregulin, also interfering with the clonogenic ability of breast
cancer cells. Based on these ﬁndings we tested the inﬂuence of WT1-
pTj on tumor cell clonogenicity. As observed, treatment with 0.5 mM
WT1-pTj drastically decreased the number of A2058 colonies both in
semi-solid soft-agar medium ( Fig. 3 B) and directly in culture plates
( Fig. 3 C), when compared to untreated or C PEP-treated cells. In the
anchorage-independent growth assay in soft-agar, treatment with
WT1-pTj reduced colony formation by 70.8%, as compared to 25.4%
with C PEP. Quantiﬁcation of cell growth on plates showed only 20
colonies after WT1-pTj treatment for 9 days, whereas cell incubation
in unsupplemented complete culture medium or with 0.5 mM PEP C,
resulted in 300 and 248 colonies, respectively. 
3.5. WT1-pTj enhances the transcriptional activity of p53 in melanoma
cells and competes with WT1 protein for binding to p53 
WT1 binds to DNA and can interact also with several intracellu-
lar proteins [ 29 ]. A physical and functional association between WT1
and the product of p53 tumor suppressor gene [ 30 ] has been demon-
strated. Such interaction was shown to cross-modulate transactiva-
tion properties. WT1 interacts with p53 through zinc ﬁngers 1 and
2, stabilizes p53, enhances p53-mediated transcriptional activation,
and antagonizes p53-mediated apoptosis triggered by ultraviolet ra-
diation [ 31 ]. 
Since the sequence of WT1-pTj covers part of a ZF motif involved
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Fig. 4. Binding of WT1-pTj to p53, displacement of p53 bound to WT1, and WT1- 
pTj modulation of transcriptional activity of p53. (A) The interaction between p53 
and WT1-pTj was determined using biotinylated peptide and CL-ELISA; * p < 0.01. (B) 
Competitive inhibition of WT1 association to p53 was evaluated in wells coated with 
recombinant p53, incubated with WT1 and then exposed to WT1-pTj or C PEP at indi- 
cated concentrations. Binding of p53 to WT1 was quantiﬁed with anti-WT1 monoclonal 
antibody; * p < 0.02 compared to C PEP effect. (C) A2058 cells were transfected with the 
p53-responsive luciferase reporter construct, and then treated with 0.5 mM WT1-pTj 
or 0.5 mM C PEP for 24 h. The ratio of ﬁreﬂy to Renilla luciferase was determined and 
normalized to the value obtained for untreated cells ( = 100%). Data are representative 
of two independent experiments. * p < 0.02 compared to Control (untreated) and C 
PEP systems. 
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Fig. 5. Effect of WT1-pTj on cell cycle progression and modulation of p53, and down- 
stream mediators, in human melanoma cells. (A) A2058 cells were treated either with 
0.5 mM WT1-pTj or 0.5 mM C PEP, for 24 h, and the cell cycle proﬁle was examined by 
ﬂow cytometry. Control, unsupplemented culture medium. Results are representative 
of three independent experiments. (B) Cellular extracts from A2058 cells exposed to 
0.5 mM WT1-pTj or 0.5 mM C PEP were subjected to immunoblotting with antibodies 
speciﬁc for p53, phospho-p53, p27, p21, phospho-cdc2 and cyclin B1. Protein load was 
normalized to β-actin. n the p53 interaction [ 31 ] we considered the possibility that the 
eptide might also bind to p53. As shown in Fig. 4 A, CL-ELISA using 
ecombinant p53 and biotinylated WT1-pTj conﬁrmed the association 
etween the peptide and the protein. In addition, using competitive 
LISA we veriﬁed that WT1-pTj dose-dependently inhibited WT1- 
53 complex formation ( Fig. 4 B). Further, in A2058 melanoma cells 
ransfected with a p53-responsive luciferase reporter construct, WT1- 
Tj (but not C PEP) enhanced p53 transcriptional activation ( Fig. 4 C). 
ogether, these results suggest that WT1-pTj interacts with p53, and 
ay decrease the association between p53 and WT1. In parallel, it 
aused p53 access to speciﬁc transcriptional response elements on 
NA. 
.6. WT1-pTj induces G2 / M cell cycle arrest and senescence features in 
uman melanoma cells 
The cell cycle of melanoma cells was examined by ﬂow cytometry 
o better characterize the mechanism by which WT1-pTj suppresses 
umor cell proliferation. Treatment with WT1-pTj effectively arrested 
he cell-cycle progression in A2058 cells, depleting the S-phase com- 
artment (from 20.2% to 6% when compared to Control) and increas- 
ng the G2 / M (from 10.5% to 27% when compared to Control) phase 
ompartment ( Fig. 5 A). A2058 cells treated with C PEP showed no sig- 
iﬁcant differences regarding the cell cycle proﬁle when compared 
o the Control system, suggesting that the ZF-coordinating region is 
ssential for the antiproliferative effects. 
In addition, we evaluated the predominant signal pathways ar- 
itrating cell cycle arrest in human melanoma cells under peptide 
reatment. As shown in Fig. 5 B, by Western blotting analysis we 
etermined that total p53 levels were not signiﬁcantly affected in 
ells treated with WT1-pTj. Nevertheless, a decrease in serine 392 
hosphorylation and an increase in serine 15 phosphorylation were 
bserved upon WT1-pTj treatment. Additionally, increased levels of 
oth p27 Kip1 and p21 Cip1 , known to regulate both G1–S and G2–M 
ransitions, were detected in WT1-pTj-treated cells. Furthermore, in order to elucidate the nature of the cell-cycle arrest caused by WT1- 
pTj, we examined the expression of cell cycle-regulating factors at 
the G2 / M phase. We found that the protein levels of cyclin B1 and 
phospho-cdc2 (Tyr15) were markedly down regulated in WT1-pTj- 
treated A2058 cells. These results associate the inhibitory effects of 
WT1-pTj to blocking of the cell cycle progression at G2 / M phase and 
modulation of p53 and downstream signaling cascades. 
Several reports have shown the central role of p53 in controlling 
senescence [ 32 ], which is characterized by stable and irreversible 
loss of cell proliferation [ 33 ]. Particularly in melanoma, telomere dys- 
function [ 34 ] oncogene activation [ 35 ] and anticancer agents [ 36 ] can 
activate p53 and its signaling partners (e.g. p16 Ink4A , Rb and p21 Cip1 ), 
which are thus implicated in the suppression of tumor initiation and 
progression. 
Owing to the up-regulation of p53 activity, along with the mor- 
phological changes (e.g. large cells and cytoplasmic vacuolization) and 
the sustained inhibition of cellular proliferation observed in WT1-pTj- 
treated cells, we hypothesized that the peptide could induce cellular 
senescence. A2058 cells were incubated with WT1-pTj, C PEP or TMZ 
(positive control) or in unsupplemented culture medium (Control), 
for 4 days. Cells were washed to remove the peptides and incubated 
for additional 4 days in fresh medium. Melanoma cells barely resumed 
proliferation after removing WT1-pTj ( Fig. 6 A). Further, as depicted 
in Fig. 6 B, the remaining cells treated with WT1-pTj exhibited altered 
morphology and stained positively for SA- β-galactosidase (72%), a 
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Fig. 6. Induction by WT1-pTj of cellular senescence in human melanoma cells. (A) 
Quantiﬁcation of colonies formed after removal of the peptides and TMZ. A2058 cells 
were treated with WT1-pTj, C PEP and TMZ for 4 days. Cells were detached and equal 
numbers of untreated and treated cells were seeded and cultivated in fresh media for 
additional 4 days. The number of colonies was scored in three independent experiments 
performed in duplicates; * p < 0.01 compared to Control and C PEP. (B) Representative 
photomicrographs (original magniﬁcation 400 × ) of A2058 cells treated with 0.5 mM 
WT1-pTj, C PEP or TMZ (positive control) for 4 days. Thereafter the peptides and TMZ 
were washed out and cells were stained for SA- β-Gal after incubation for additional 3 
days in fresh media. Positive cells for SA- β-Gal were visualized under a phase contrast 
microscope and expressed as percentage of total cells counted at random. (C) Acridine 
orange was used to stain acidic vesicular organelles in untreated control cells (a); serum 
starved cells for 24 h (positive control) (b); cells treated with 0.5 mM WT1-pTj (c); 
cells treated with C PEP (d), for 4 days. Images are representative of two independent 
experiments performed in duplicates. Bars = 10 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 widely used senescence biomarker [ 36 ]. In contrast, C PEP caused
little reduction in the number of colonies as compared to untreated
cells, and a minor effect on senescence induction (16%) when com-
pared to WT1-pTj. Thus, the proliferative capacity of WT1-pTj-treated
cells was lost even upon removal of the peptide. 
The SA- β-galactosidase has been shown to be a manifestation of
residual lysosomal activity after alkalinization, only detectable due
to the increased lysosomal content in senescent cells [ 37 ]. Therefore,
we examined the lysosomal content in melanoma cells treated either
with WT1-pTj or C PEP, using the lysosomotropic agent acridine or-
ange. Staining of A2058 cells with acridine orange showed a marked
increase in the number and size of lysosomes in senescent cells after
treatment with 0.5 mM WT1-pTj for 4 days as visualized by ﬂuores-
cence microscopy ( Fig. 6 C). Most of the C PEP-treated cells exhib-
ited minimal red ﬂuorescence. These results, along with the molecu-
lar mechanism underlying WT1-pTj-induced growth arrest, strongly
suggest that WT1-pTj-treated cells undergo cellular senescence. 
4. Discussion 
Peptide-based antitumor therapy explores the high afﬁnity and
speciﬁcity of peptides for particular targets, the low toxicity and goodtissue penetration [ 38 ]. Our laboratory has focused on antitumor pep-
tides derived from internal sequences of immunoglobulins and tran-
scription factors [ 22 ]. In the current study, we report on a peptide
derived from WT1, endowed with anti-melanoma properties. Both
human melanoma and B16F10 murine melanoma were sensitive to
the WT1-pTj Trojan peptide. 
WT1 called our attention due to its high expression and immuno-
genicity in B16F10 murine melanoma (unpublished results). In com-
parison with human cancer, WT1 has emerged as an important target
expressed in hematologic and solid tumors. There is, indeed, plenty
of evidence supporting the role of WT1 in the oncogenic process of
melanoma. The function of WT1 in transcriptional regulation, as well
in RNA metabolism and translation, has been extensively reviewed
[ 25 , 39 ]. WT1 overexpression has been detected in melanoma patients ’
samples and melanoma cells, whereas no WT1 staining has been ob-
served in the majority of benign melanocytic nevi, epidermal ker-
atinocytes and melanocytes [ 4 , 40 ]. RNAi silencing of WT1 inhibited
melanoma proliferation associated with down-regulation of nestin
and zyxin [ 6 ], sensitized B16F10 cells to conventional chemothera-
peutic agents (e.g. doxorubicin and cisplatin) and reduced lung metas-
tases, emphasizing WT1 function in melanoma progression [ 8 ]. 
The WT1-pTj peptide contains part of a particularly reactive zinc-
ﬁnger domain, and owing to its abundant basic amino acid compo-
sition, exhibits cell-penetrating properties. The peptide was able to
arrest tumor cell growth and induce senescence in human melanoma
cells. A signiﬁcant antimelanoma activity in vivo was also observed
using subcutaneous and metastatic models in mice. Increased levels
of active p53 and enhanced transcriptional activation were associ-
ated with WT1-pTj-induced senescence in A2058 human melanoma
cells. Cyclin-dependent kinase inhibitors p27 Kip1 and p21 Cip1 medi-
ated the sustained cell cycle arrest. The typical senescent phenotype
in WT1-pTj-treated cells included enlarged cytoplasm, and cellular
increase of both SA- β-galactosidase activity and lysosomal content.
To exert its activities, peptide WT1-pTj, like WT1, does not bind to
p53 promoter but physically interacts with the p53 protein itself. In
fact, we have shown that the peptide competes with WT1 for protein
binding to p53, supporting the hypothesis that the peptide may pre-
vent important interactions of WT1 with its partners, including p53,
and therefore disturb relevant pro-tumor signaling of the original
protein via the ZF domain. Protein-protein interaction of WT1 with
p53 modulates binding to different promoters determining gene ex-
pression or repression. As with WT1, we demonstrated that peptide
WT1-pTj activated p53 to act as a transcription factor in a luciferase
gene expression system. 
Therapy-induced senescence is a novel therapeutic approach to
treat cancers [ 41 ]. Standard chemotherapy and radiotherapy, besides
inducing DNA damage and cytotoxicity, may trigger a robust senes-
cence response in vitro and in vivo [ 42 , 43 ]. Pro-senescence therapy
may also be achieved with greatly reduced toxicity. 
The molecular mechanism underlying therapy-induced senes-
cence conferred by WT1-pTj treatment depends on p53 transcrip-
tional activation and is correlated with p53 post-transcriptional phos-
phorylation at Ser15 and Ser392. Consistent with previous ﬁndings
that have reported on speciﬁc changes in p53, a sustained treat-
ment triggers a p53-dependent senescence program. Prolonged β-
interferon stimulation switched on p53 in two steps involving ﬁrst,
dephosphorylation at serine 392, and then, phosphorylation of p53 at
serine 15 leading to its transcriptional activity [ 44 ]. Similar posttrans-
lational modiﬁcations of p53 were observed in replicative senescence
in human ﬁbroblasts [ 45 ]. 
Likewise in WT1-pTj induced senescence of melanoma cells, re-
duced phosphorylation at S392 and increased phosphorylation at S15,
were observed. Activation of p53 by phosphorylation, rendering an
important effector of senescence [ 46 , 47 ] leads to the transcriptional
activation of target genes. In agreement, we observed the induction of
the senescence molecular markers p21 Cip1 and p27 Kip1 [ 41 ] in A2058
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Rells exposed to WT1-pTj. Our results excluded p16 Ink4A -Rb signal ac- 
ivation in WT1-pTj-induced cellular senescence (data not shown), in 
ine with previous data showing that p16 is frequently inactivated in 
elanoma [ 48 , 49 ]. 
Cell cycle analysis revealed that WT1-pTj inhibition of melanoma 
ell proliferation was caused by cell cycle arrest at G2 / M phase, ac- 
ompanied by a decrease in the number of cells in the S phase. The 
2–M transition is positively regulated by Cdc2 / cyclin B complex 
 50 ], which is controlled by phosphorylation at various sites, includ- 
ng the inhibitory phosphorylation at tyrosine-15 and threonine 14 
y Wee1 and Myt1 [ 51 , 52 ]. A decrease in the levels of phospho-cdc2 
Tyr15), cdc2, cyclin A and cyclin B1 has been associated with cell 
ycle arrest at G2 / M [ 53 ]. Similarly, we found a signiﬁcant decrease 
n cyclin B1 and phospho-cdc2 (Tyr15) expression after treatment 
ith WT1-pTj, in contrast with C PEP-treated cells. In conclusion, 
odulation of p53 activity and activation of downstream signaling 
s essential for senescence response in WT1-pTj-treated cells. These 
vents depend on the ZF-coordinating region because C PEP elicited 
o similar response. 
Given the limited expression of WT1 in adult animals, restricted to 
ew cell types of the urogenital system [ 3 ], this factor might otherwise 
e an optimal target for treatment of WT1-expressing malignancies. 
n the ﬁeld of targeted therapies, CPPs (cationic cell-penetrating pep- 
ides) have been used to overcome permeability barriers in the tumor 
nd to mediate cargo delivery into cancer cells, leading to the de- 
elopment of tumor-speciﬁc molecular therapeutics. CPP-mediated 
ransduction has been used to inhibit nuclear oncoprotein translo- 
ation [ 54 ], modulate oncoprotein signaling [ 10 ], enable apoptotic 
ell-death [ 16 , 55 ], and deliver oligonucleotides [ 56 ] to cancer cells. 
resently, we show that peptide WT1-pTj exhibits trojan properties 
nd exerts protective effects in experimental melanoma therapy. In 
ddition to antiproliferative effects mediated by WT1-pTj treatment 
n vitro , the peptide inhibited human melanoma progression, in nude 
ice. 
Conventional chemotherapeutic drugs act mainly through induc- 
ion of apoptosis, and their reduced efﬁcacy in melanoma patients 
s related to the high resistance of melanoma cells [ 57 ]. Therapy- 
nduced senescence may represent an alternate functional approach 
o improve cancer therapy [ 58 , 59 ]. 
To conclude, our present study reports on the senescence-inducing 
eptide WT1-pTj as a promising candidate to eradicate tumor cell 
rogression, including those that fail to respond to conventional an- 
itumor therapies. The WT1-pTj is unique in that it derives from an 
ncoprotein, is cell-penetrating by itself, induces cellular senescence 
nd effectively protects in a cancer preclinical model. 
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